Bringing the Oncology Community Together

Dr. Wetzler on Autologous Transplantation in Ph+ALL

Meir Wetzler, MD
Published Online: Tuesday, December 18, 2012
Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

The authors of the study hypothesized that an imatinib and sequential chemotherapy regimen would allow for the collection of a patient’s normal hematopoietic stem cells not contaminated by residual BCR/ABL+ lymphoblasts and reduce the likelihood of relapse after an autologous transplantation.

The study found that autologous transplantation is a safe and effective alternative to allogeneic transplantation for patients with Ph+ALL.

Related Articles
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Hitting the Target: How Druker’s Persistence Helped Launch a New Mode of Attack
Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.
Dr. Flynn on CDK Inhibitors for the Treatment of CLL
Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.